Groundbreaking Research

From its inception, Mary Crowley Cancer Research has focused on personalized, cancer-specific therapeutics as the gateway to cancer control and to a higher probability of cure.

In this effort, Mary Crowley has functioned not only as a conduit of state-of-the-art treatment modalities but also as an innovator and contributor to conceptual development and translational applications.

Featured Publications

See All

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab- Paclitaxel in Patients with Advanced Solid Tumors

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).

Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.

Featured Abstracts

See All

Pharmacodynamic and Response Biomarkers in the Monotherapy Arm MBINATION OF DLL4/VEGF-A BLOCKADE AND IMMUNOMODULATION CAN ELIMINATE MHC CLASS I NEGATIVE TUMORS IN MICE of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody

DRAGON Trial: Durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor resistant advanced cancers

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

A phase 1 multicenter study of the safety and efficacy of the NKG2A targeting antibody S095029 as single agent and in combination with anti-PD1 in patients with advanced malignancies

Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity

Comparative Assessment of Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK210(EGFR) to ex vivo Diakine Response Assay

First-in-Human Results of STX-478, A Mutant-Selective PI3Ka Inhibitor, in HR+ Breast Cancer and Advanced Solid Tumor Patients

A Phase 1, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 (4-1BB x PD-L1 BsAb) in Patients with Advanced or Metastatic Solid Tumors

Overall Survival Results of BRIA-IMT Allogenic Whole Cell-Based Cancer Vaccine

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Featured White Papers

See All

CLINICAL UPDATE OF BI-SHRNA FURIN/GMCSF DNA TRANSFECTED TUMOR VACCINE: FANG IN CANCER PATIENTS

Mary Crowley presented at the American Society of Gene and...

PERSONALIZED (AKA PRECISION) THERAPY-A SYSTEMS ANALYSIS OF CAPTURED MOLECULAR DATA

There are eight hallmark biological capabilities necessary for cancer development...

PHASE II CLINICAL TRIAL OF A GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-ENCODING, SECOND-GENERATION ONCOLYTIC HERPESVIRUS

Treatment options for metastatic melanoma are limited. We conducted this...

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000

Groundbreaking Research

Featured Publications

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab- Paclitaxel in Patients with Advanced Solid Tumors

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).

Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.

Featured Abstracts

Pharmacodynamic and Response Biomarkers in the Monotherapy Arm MBINATION OF DLL4/VEGF-A BLOCKADE AND IMMUNOMODULATION CAN ELIMINATE MHC CLASS I NEGATIVE TUMORS IN MICE of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody

DRAGON Trial: Durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor resistant advanced cancers

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

A phase 1 multicenter study of the safety and efficacy of the NKG2A targeting antibody S095029 as single agent and in combination with anti-PD1 in patients with advanced malignancies

Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity

Comparative Assessment of Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK210(EGFR) to ex vivo Diakine Response Assay

First-in-Human Results of STX-478, A Mutant-Selective PI3Ka Inhibitor, in HR+ Breast Cancer and Advanced Solid Tumor Patients

A Phase 1, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 (4-1BB x PD-L1 BsAb) in Patients with Advanced or Metastatic Solid Tumors

Overall Survival Results of BRIA-IMT Allogenic Whole Cell-Based Cancer Vaccine

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Featured White Papers

CLINICAL UPDATE OF BI-SHRNA FURIN/GMCSF DNA TRANSFECTED TUMOR VACCINE: FANG IN CANCER PATIENTS

CLINICAL UPDATE OF BIFUNCTIONAL (BI)-SHRNAI NANOPLEX TECHNOLOGY IN CANCER

HUMAN GENOME

MELANOMA

MOLECULAR MAPPING FOR PERSONALIZED CANCER THERAPEUTICS

PERSONALIZED (AKA PRECISION) THERAPY-A SYSTEMS ANALYSIS OF CAPTURED MOLECULAR DATA

PHASE II CLINICAL TRIAL OF A GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-ENCODING, SECOND-GENERATION ONCOLYTIC HERPESVIRUS

Connect With Us